Conspicuous Consumption: TB Therapies Are A Priority At FDA
Executive Summary
A June 3 advisory committee discussion of tuberculosis drug development offers a good early case study of how the Hamburg FDA may benefit some classes of drug development
You may also be interested in...
TB Study Lights Pathway Toward Combination Drug Trial Guidance
A clinical trial of three new tuberculosis drugs, along with one that is used in standard therapy, exemplifies FDA's evolving approach to studies that combine more than one investigational drug.
TB Study Lights Pathway Toward Combination Drug Trial Guidance
A clinical trial of three new tuberculosis drugs, along with one that is used in standard therapy, exemplifies FDA's evolving approach to studies that combine more than one investigational drug.
Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.
The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting